Wentao Wu
Geschäftsführer bei Xynomic Pharmaceuticals, Inc.
Aktive Positionen von Wentao Wu
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Xynomic Pharmaceuticals, Inc.
 Xynomic Pharmaceuticals, Inc. BiotechnologyHealth Technology Xynomic Pharmaceuticals, Inc. operates as biopharmaceutical company. It develops and commercializes innovative oncology drugs to address unmet medical needs in solid tumor and hematological malignancies and to improve cancer patients’ life expectancy and treatment prognosis. The company was founded by Yinglin Mark Xu in 2016 and is headquartered in Dover, DE. | Geschäftsführer | - | - |
Karriereverlauf von Wentao Wu
Ehemalige bekannte Positionen von Wentao Wu
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| AMERICAN ORIENTAL BIOENGINEERING, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2004 | 01.01.2009 |
Hutchison MediPharma Ltd.
 Hutchison MediPharma Ltd. Medical SpecialtiesHealth Technology Hutchison MediPharma Ltd. discovers and develops innovative human therapeutics. Its products include savolitinib, fruqnitinib, sulfatinib, HMPL-523, epitinib, theliatinib, HMPL-453, HMPL-689 and HMPL-004. The company was founded by Ying Samantha Du in September 2002 and is headquartered in Shanghai, China. | Corporate Officer/Principal | 01.01.2002 | 01.01.2004 |
| XYNOMIC PHARMACEUTICALS HOLDINGS, INC. | Geschäftsführer | 01.01.2019 | - |
Ausbildung von Wentao Wu
| Purdue University | Doctorate Degree |
| Indiana University | Masters Business Admin |
Statistik
International
| Vereinigte Staaten | 5 |
| China | 3 |
Operativ
| Chief Operating Officer | 2 |
| Doctorate Degree | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
Sektoral
| Health Technology | 5 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| AMERICAN ORIENTAL BIOENGINEERING, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Xynomic Pharmaceuticals Holdings, Inc.
 Xynomic Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Xynomic Pharmaceuticals Holdings, Inc. is a clinical stage best-in-class oncology therapeutics biopharmaceutical company. It engages in licensing, developing and commercializing oncology drug candidates in China, US, and rest of the world. Its current pipeline mainly consists of 3 drug candidates; Xynomic owns global exclusive development, manufacturing and commercialization rights to each of these. Its lead drug candidate abexinostat is in global potentially pivotal clinical trials against renal cell carcinoma and non-Hodgkin's lymphoma. The company was founded by Yinglin Mark Xu on October 7, 2016 and is headquartered in Shanghai, China. | Health Technology |
Hutchison MediPharma Ltd.
Hutchison MediPharma Ltd. Medical SpecialtiesHealth Technology Hutchison MediPharma Ltd. discovers and develops innovative human therapeutics. Its products include savolitinib, fruqnitinib, sulfatinib, HMPL-523, epitinib, theliatinib, HMPL-453, HMPL-689 and HMPL-004. The company was founded by Ying Samantha Du in September 2002 and is headquartered in Shanghai, China. | Health Technology |
Xynomic Pharmaceuticals, Inc.
Xynomic Pharmaceuticals, Inc. BiotechnologyHealth Technology Xynomic Pharmaceuticals, Inc. operates as biopharmaceutical company. It develops and commercializes innovative oncology drugs to address unmet medical needs in solid tumor and hematological malignancies and to improve cancer patients’ life expectancy and treatment prognosis. The company was founded by Yinglin Mark Xu in 2016 and is headquartered in Dover, DE. | Health Technology |
